Display options
Share it on

Nutr Metab (Lond). 2021 Mar 10;18(1):26. doi: 10.1186/s12986-021-00553-4.

Integrative proteomic and lipidomic analysis of Kaili Sour Soup-mediated attenuation of high-fat diet-induced nonalcoholic fatty liver disease in a rat model.

Nutrition & metabolism

Shuo Cong, Zhengchao Li, Lei Yu, Yongmei Liu, Yaxin Hu, Ying Bi, Mingliang Cheng

Affiliations

  1. School of Basic Medicine Sciences, Guizhou Medical University, Guiyang City, China.
  2. Guizhou Cancer Hospital, Guiyang City, China.
  3. Graduate School of Guizhou Medical University, Guiyang City, China.
  4. Maternal and Child Health Hospital of Guiyang City, Guiyang City, China.
  5. Department of Infectious Diseases, Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang City, 550004, Guizhou Province, China.
  6. Department of Infectious Diseases, Affiliated Hospital of Guizhou Medical University, 28 Guiyi Street, Guiyang City, 550004, Guizhou Province, China. [email protected].

PMID: 33691721 PMCID: PMC7945315 DOI: 10.1186/s12986-021-00553-4

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease and is characterized by excessive fat accumulation. Kaili Sour Soup, a food typical of Guizhou Province, is believed to have significant health benefits. Thus, we aimed to identify and assess the impact of Kaili Sour Soup on NAFLD and its underlying mechanism using integrative proteomic and lipidomic analysis.

METHODS: A high-fat diet and male Wistar rats were used to construct a NAFLD rat model. Haematoxylin and eosin (HE) and Oil Red O staining analyses were used to perform the histologic examination. Proteomic analysis was utilized to systematically identify the global protein profile in NAFLD with and without Kaili Sour Soup treatment. Western blot assays were used to verify the expression of proteins screened by proteomic analysis. Lipidomic analysis was performed to screen lipid metabolism in NAFLD with and without Kaili Sour Soup treatment.

RESULTS: Kaili Sour Soup alleviated high-fat diet (HFD)-induced fatty liver and had a normalizing effect on physiological and biochemical indicators of NAFLD, including body weight, liver weight, liver index, total cholesterol (TC), triglyceride (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and insulin resistance level of homeostasis model assessment (HOMA-IR). Kaili Sour Soup decreased the levels of 13 proteins (Tmem44, Rnaseh2b, Gstm6l, LOC100910877, Rufy4, Slc12a2, Pcif1, P4503A1, Sult1e1, Nop53, AABR07065656.4, AABR07065789.3) that were upregulated by HFD and increased the levels of 3 proteins (Sult1c2, Sult1c2a, Snrnp48) that were downregulated by HFD. Kaili Sour Soup attenuated the HFD-induced increase in acyl carnitine (AcCa) and enhanced the HFD-induced decreases in gangliosides (GM3) and lysophosphatidylserine (LPS) in the NAFLD rat model.

CONCLUSIONS: Altogether, this study revealed that Kaili Sour Soup attenuated HFD-induced fatty liver and systematically identified abnormal proteins and lipids involved in the role of Kaili Sour Soup in a NAFLD rat model.

Keywords: Kaili Sour Soup; Lipidomics; Nonalcoholic fatty liver disease; Proteomics

References

  1. Mol Metab. 2014 May 20;3(5):565-80 - PubMed
  2. Hepatology. 2019 Oct;70(4):1457-1469 - PubMed
  3. Curr Opin Clin Nutr Metab Care. 2017 Mar;20(2):110-116 - PubMed
  4. J Clin Invest. 2010 Oct;120(10):3713-21 - PubMed
  5. Nutrients. 2017 Sep 06;9(9): - PubMed
  6. J Biol Chem. 2008 Nov 28;283(48):33736-49 - PubMed
  7. ACS Omega. 2020 Apr 29;5(20):11314-11323 - PubMed
  8. Nature. 2014 May 15;509(7500):282-3 - PubMed
  9. J Endocrinol. 2012 Oct;215(1):59-70 - PubMed
  10. Ann Intern Med. 1997 Jan 15;126(2):137-45 - PubMed
  11. PLoS One. 2017 Feb 17;12(2):e0172348 - PubMed
  12. Curr Pharm Biotechnol. 2012 Apr;13(5):726-35 - PubMed
  13. Antioxid Redox Signal. 2012 Dec 1;17(11):1580-9 - PubMed
  14. Environ Toxicol Pharmacol. 2016 Jul;45:52-62 - PubMed
  15. Eur J Biochem. 1992 Jan 15;203(1-2):107-13 - PubMed
  16. Xenobiotica. 2011 Jun;41(6):494-500 - PubMed
  17. Metabolism. 2018 Jun;83:1-10 - PubMed
  18. J Lipid Res. 1978 Jul;19(5):538-43 - PubMed
  19. Diabetes. 2013 Jan;62(1):1-8 - PubMed
  20. Can J Gastroenterol Hepatol. 2014 Dec;28(11):607-18 - PubMed
  21. Hepatobiliary Pancreat Dis Int. 2013 Apr;12(2):125-35 - PubMed
  22. J Clin Invest. 1994 May;93(5):2007-13 - PubMed
  23. PLoS One. 2017 Aug 10;12(8):e0181052 - PubMed
  24. Cell Mol Life Sci. 2018 Sep;75(18):3313-3327 - PubMed
  25. J Endocrinol. 2015 Dec;227(3):153-65 - PubMed
  26. BMC Bioinformatics. 2014;15 Suppl 7:S9 - PubMed
  27. Xenobiotica. 2009 Dec;39(12):889-902 - PubMed
  28. Nat Methods. 2009 May;6(5):359-62 - PubMed
  29. Free Radic Biol Med. 2019 Nov 20;144:293-309 - PubMed
  30. J Womens Health (Larchmt). 2015 Dec;24(12):969-71 - PubMed
  31. Front Cell Dev Biol. 2019 Oct 25;7:248 - PubMed
  32. J Lipid Res. 2015 Mar;56(3):722-36 - PubMed

Publication Types

Grant support